세파크롤(Cefaclor) 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 판매채널별, 최종 용도별, 지역별, 경쟁별(2020-2030년)

Global Cefaclor market was valued at USD 418.19 million in 2024 and is projected to reach USD 583.30 million by 2030, expanding at a compound annual growth rate (CAGR) of 3.77% over the forecast period. This steady market growth is underpinned by the widespread use of cefaclor-a second-generation cephalosporin antibiotic-commonly prescribed for the treatment of respiratory tract infections, urinary tract infections, skin infections, and other bacterial conditions. Cefaclor's broad-spectrum efficacy, favorable safety profile, and established clinical utility continue to support its strong positioning in outpatient therapeutic settings.

Market growth is further reinforced by the rising global incidence of bacterial infections, increasing healthcare awareness, and enhanced access to antibiotics-particularly in developing regions. Notably, markets in Asia-Pacific and Latin America are experiencing accelerated demand, driven by improvements in healthcare infrastructure and urbanization. Meanwhile, North America and Europe maintain mature markets due to well-established pharmaceutical distribution networks and stable prescription volumes.

Despite these favorable trends, the cefaclor market faces notable challenges. Chief among them are the growing concerns surrounding antimicrobial resistance (AMR) and regulatory pressures to implement stringent antibiotic stewardship protocols. Health authorities across the globe are enforcing tighter controls on antibiotic use to counter the emergence of resistant bacterial strains. While these initiatives are critical for safeguarding public health, they may impact the prescribing frequency of cefaclor and incentivize the development and adoption of newer antimicrobial alternatives.

Key Market Drivers

Healthcare Sector Expansion

The continued expansion of the global healthcare sector remains a key driver of cefaclor market growth. The global hospital market is projected to generate approximately USD 4.41 trillion in revenue by 2025, with the United States expected to contribute USD 1.55 trillion. In parallel, U.S. hospitals are significantly investing in telemedicine to broaden healthcare access-especially in rural and underserved communities.

Emerging economies are witnessing similar trends, with growing investments in healthcare infrastructure fueling demand for widely used antibiotics such as cefaclor. For instance, India's Union Budget 2025-26 allocated USD 11.50 billion toward healthcare, emphasizing system development and capacity building. The government also plans to launch a USD 6.80 billion credit incentive scheme to attract further investments into healthcare infrastructure.

These public and private sector investments are facilitating the expansion of hospitals, diagnostic services, and healthcare personnel. As access to medical care improves-particularly in previously underserved regions-diagnosis and treatment rates are rising, thereby driving higher prescription volumes of broad-spectrum antibiotics like cefaclor.

Key Market Challenges

Rising Antimicrobial Resistance (AMR)

The global escalation of antimicrobial resistance (AMR) presents a significant barrier to the growth of the cefaclor market. Resistance among bacterial strains is reducing the clinical effectiveness of widely used antibiotics, including second-generation cephalosporins such as cefaclor. This trend not only compromises treatment outcomes but also dampens overall demand for the drug.

AMR has become a major global health concern, fueled by the overuse and inappropriate prescription of antibiotics in both human healthcare and agriculture. In many regions, antibiotics like cefaclor are frequently administered without adequate diagnostic justification or are misused for viral infections, accelerating the emergence of resistant strains. Consequently, the therapeutic reliability of cefaclor for treating infections such as bronchitis, otitis media, and urinary tract infections is increasingly being called into question.

Key Market Trends

Rising Incidence of Bacterial Infections

The increasing prevalence of bacterial infections represents a significant trend shaping the cefaclor market. The 2024 WHO Bacterial Priority Pathogens List (BPPL) highlights 24 high-risk pathogens across 15 bacterial families, including Gram-negative bacteria resistant to last-resort antibiotics and drug-resistant strains such as Mycobacterium tuberculosis, Salmonella, Shigella, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Staphylococcus aureus.

These pathogens have been identified as global threats due to their high transmission potential, limited treatment options, and widespread burden. In this context, cefaclor continues to be a vital therapeutic agent, especially in addressing respiratory tract infections, skin infections, otitis media, and urinary tract infections.

The surge in treatable respiratory infections-such as pharyngitis, bronchitis, and pneumonia-is particularly notable among pediatric and elderly populations, where immune vulnerability is greater. As healthcare systems respond to seasonal infection cycles and the ongoing repercussions of recent viral pandemics, the demand for reliable, broad-spectrum antibiotics like cefaclor remains robust.

Key Market Players

• ACS DOBFAR
• Qilu Antibiotics Pharmaceutical
• Zhejiang Anglikang Pharmaceutical Co., Ltd.
• Zhejiang Dongbang Pharmaceutical Co., Ltd.
• Zhejiang East Asia Pharmaceutical Co., Ltd.
• Zhejiang Zhebang Pharmaceutical Co., Ltd
• Centrient Pharmaceuticals (Zibo)
• Conscientia Industrial Co., Ltd
• Dhanuka Laboratories Ltd.
• Lupin Limited

Report Scope

In this report, the Global Cefaclor Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cefaclor Market, By Sales Channel:

• Direct
• Indirect

Cefaclor Market, By End Use:

• Lung Infection
• Skin Infection
• Ear Infection
• Throat Infection
• Tonsils
• Urinary Tract Infection
• Others

Cefaclor Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cefaclor Market.

Available Customizations:

Global Cefaclor Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Cefaclor Market

5. Global Cefaclor Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Sales Channel (Direct, Indirect)
  • 5.2.2. By End Use (Lung Infection, Skin Infection, Ear Infection, Throat Infection, Tonsils, Urinary Tract Infection, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Cefaclor Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Sales Channel
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cefaclor Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Sales Channel
      • 6.3.1.2.2. By End Use
  • 6.3.2. Mexico Cefaclor Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Sales Channel
      • 6.3.2.2.2. By End Use
  • 6.3.3. Canada Cefaclor Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Sales Channel
      • 6.3.3.2.2. By End Use

7. Europe Cefaclor Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Sales Channel
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Cefaclor Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Sales Channel
      • 7.3.1.2.2. By End Use
  • 7.3.2. Germany Cefaclor Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Sales Channel
      • 7.3.2.2.2. By End Use
  • 7.3.3. United Kingdom Cefaclor Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Sales Channel
      • 7.3.3.2.2. By End Use
  • 7.3.4. Italy Cefaclor Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Sales Channel
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Cefaclor Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Sales Channel
      • 7.3.5.2.2. By End Use

8. Asia Pacific Cefaclor Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Sales Channel
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cefaclor Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Sales Channel
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Cefaclor Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Sales Channel
      • 8.3.2.2.2. By End Use
  • 8.3.3. South Korea Cefaclor Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Sales Channel
      • 8.3.3.2.2. By End Use
  • 8.3.4. Japan Cefaclor Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Sales Channel
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Cefaclor Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Sales Channel
      • 8.3.5.2.2. By End Use

9. South America Cefaclor Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Sales Channel
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cefaclor Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Sales Channel
      • 9.3.1.2.2. By End Use
  • 9.3.2. Argentina Cefaclor Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Sales Channel
      • 9.3.2.2.2. By End Use
  • 9.3.3. Colombia Cefaclor Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Sales Channel
      • 9.3.3.2.2. By End Use

10. Middle East and Africa Cefaclor Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Sales Channel
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cefaclor Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Sales Channel
      • 10.3.1.2.2. By End Use
  • 10.3.2. Saudi Arabia Cefaclor Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Sales Channel
      • 10.3.2.2.2. By End Use
  • 10.3.3. UAE Cefaclor Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Sales Channel
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cefaclor Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. ACS DOBFAR
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Qilu Antibiotics Pharmaceutical
• 15.3. Zhejiang Anglikang Pharmaceutical Co., Ltd.
• 15.4. Zhejiang Dongbang Pharmaceutical Co., Ltd.
• 15.5. Zhejiang East Asia Pharmaceutical Co., Ltd.
• 15.6. Zhejiang Zhebang Pharmaceutical Co., Ltd
• 15.7. Centrient Pharmaceuticals (Zibo)
• 15.8. Conscientia Industrial Co., Ltd
• 15.9. Dhanuka Laboratories Ltd.
• 15.10. Lupin Limited

16. Strategic Recommendations

17. About Us & Disclaimer